Daily TIP

The Daily TIP: Iran-Backed Hezbollah Commander: We Hope to Fight Israel “in the Galilee Someday Soon” -

Posted by Tip Staff - July 31, 2017

Hezbollah Commander: We Hope to Fight Israel "in the Galilee Someday Soon"
WaPo: No "Evidence of the Lebanese State" in Border Area Held by Hezbollah
North Carolina Becomes 22nd State to Ban Discriminatory Boycotts of Israel
Revolutionary Israeli ALS Therapy Receives FDA Approval for Phase 3 Clinical Trials in U.S.

Hezbollah Commander: We Hope to Fight Israel "in the Galilee Someday Soon"

A Hezbollah commander said that the Iranian proxy group plans to bring its war against Israel to "the Galilee someday soon," Buzzfeed News reported Sunday.

The outlet reported on Iran's multinational network of tens of thousands of highly trained and experienced combatants from across the Middle East, which Tehran uses to fulfill its imperial ambitions in Syria, Iraq, Lebanon, and Yemen.

Under the radar of the international community, which is still transfixed on the 2015 nuclear agreement and wholly unprepared to confront Iran’s aggressive behavior, Tehran is seeking to establish a Shia Crescent reaching from the Gulf of Aden to the shores of the Mediterranean.

Ever since the U.S.-led invasion of Iraq in 2003, the Iranians have had their eyes on their Shiite-majority neighbor, infiltrating the country’s government, commerce, and military infrastructure.

As early as 2013, The Wall Street Journal reported on the Iranian effort to marshal Shiites from across the Middle East to protect embattled Syrian President Bashar al-Assad.

“What we learn, we used on the ground in [southern Lebanon] against the Israelis in 2006," Hoder, a Hezbollah commander boasted to BuzzFeed. “And hopefully, in the Galilee someday soon,” he added, making no secret of Tehran’s goal to use Syria in its fight against Israel.

More recently, U.S. and other officials have warned of Iran’s increased meddling in the Yemeni civil war on behalf of the Shiite Houthi rebels, responsible for recent attacks on ships off the coast of Yemen that could cripple crucial sea lanes.

WaPo: No "Evidence of the Lebanese State" in Border Area Held by Hezbollah

In a tour for reporters of the areas that Hezbollah's forces captured last week in northeastern Lebanon, "nowhere was there any evidence of the Lebanese state," correspondents for The Washington Post reported on Saturday.

While the declared intent of the tour was to dispel charges made by United States President Donald Trump last week that Hezbollah is a terrorist group, the report showed the tight control Hezbollah exercises over Lebanon.

"For the most part, the area is empty, an arid wilderness of ungoverned space devoid of habitation. Hezbollah outposts, flying yellow Hezbollah flags alongside those of Lebanon, are few and far between," the report described the surroundings. "Tents labeled as belonging to the Iranian Red Crescent are erected at some of the posts, presumably to supply medical aid to the fighters. There is no sign of its Lebanese equivalent."

“Basically Hezbollah has two strengths when it comes to how it shapes political and military outcomes,” observed Aram Nerguizian of the Washington-based Center for Strategic and International Studies. “It’s incredibly media savvy and understands the power of optics. And it has freedom of action that no state actor has, including the Lebanese Army, or any political faction,” he added effectively confirming the reporters' observation about Hezbollah's strength in contrast to that of the Lebanese government.

Because of the Iranian-backed terror group's influence, experts have concluded that boosting Lebanon's army to fight Hezbollah will be counterproductive, as Hezbollah has effective control over all Lebanese institutions including the army.

North Carolina Becomes 22nd State to Ban Discriminatory Boycotts of Israel

North Carolina Democratic Gov. Roy Cooper signed legislation on Thursday prohibiting the state from doing business with companies that boycott Israel.

The bipartisan bill, which passed North Carolina's House of Representatives by a vote of 96-19 and Senate by a vote of 45-3 last month, also requires the state to divest from any existing business dealings with entities that boycott Israel, the Jewish Telegraphic Agency reported.

“This bill makes it clear that the State of North Carolina stands with Israel, which has long been an important trading partner of North Carolina,” observed Carin Savel, CEO of the Jewish Federation of Raleigh-Cary.

North Carolina does an estimated $140 million worth of business with Israel every year.

Similar anti-BDS bills have become law in Michigan, Pennsylvania, Illinois, South Carolina, Arizona, Georgia, Colorado, Florida, Alabama, California, New Jersey, Ohio, Rhode Island, Arkansas, Minnesota, Nevada, Kansas, and Iowa. New York governor Andrew Cuomo approved a similar measure by executive order.

Advocates of these measures have emphasized that they do not raise any First Amendment issues, as private parties are still free to protest, boycott, or speak out against Israel in any way. However, states may be obligated to protect taxpayer money from being used to promote or support discrimination based on religion, race, or nationality.

Revolutionary Israeli ALS Therapy Receives FDA Approval for Phase 3 Clinical Trials in U.S.

BrainStorm Cell Therapeutics of Petah Tikva is recruiting American patients for a Phase 3 clinical study of its NurOwn stem-cell treatment intended to halt progression of amyotrophic lateral sclerosis (ALS).

The NurOwn platform grew out of a technique developed at Tel Aviv University for growing and enhancing stem cells harvested from patients’ own bone marrow. The enhanced cells, injected via lumbar puncture, secrete elevated levels of nerve-growth factors believed to protect existing motor neurons, promote motor neuron growth and reestablish nerve-muscle interaction.

A 24-week Phase 2 safety study was concluded in 2016 on 48 participants (36 treated, 12 placebo) with possible, probable and definite ALS. This study was done at the University of Massachusetts Medical School, Massachusetts General Hospital and the Mayo Clinic.

The Phase 3 double-blind, placebo-controlled study, to begin enrollment in August, will look at efficacy and safety of repeated doses. The California Institute for Regenerative Medicine has awarded Brainstorm a $16 million grant to support the pivotal trial.

BrainStorm President and CEO Chaim Lebovits said he hopes to get approval by the end of the year for a hospital exemption program in Israel — an accelerated regulatory pathway – that would clear the way for a first batch of 50 patients to receive NurOwn at Tel Aviv Sourasky Medical Center. However, there will be no “compassionate treatment” using NurOwn in Israel or elsewhere.

The NurOwn platform technology also has potential applications in any neurodegenerative disease, such as multiple sclerosis and Parkinson’s.

(via Israel21c)

Be the first to comment

Please check your e-mail for a link to activate your account.